Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states
Immunovia, Inc. has secured Clinical Laboratory permits from the Pennsylvania and Maryland Departments of Health, enabling physicians in these states to order the IMMray™ PanCan-d test for early pancreatic cancer detection. This permits expansion, now allowing the test to be offered in 48 US states. CEO Jeff Borcherding noted the importance of enhancing pancreatic cancer surveillance. The IMMray™ PanCan-d test is the only blood test available specifically for this purpose and aims to improve survival rates in high-risk patients.
- Secured Clinical Laboratory permits from Pennsylvania and Maryland.
- IMMray™ PanCan-d test is now available in 48 US states.
- The only blood test for early detection of pancreatic cancer.
- None.
LUND, Sweden, May 23, 2022 /PRNewswire/ -- The Pennsylvania and Maryland Departments of Health have granted Immunovia, Inc., the US subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Clinical Laboratory permits, allowing physicians in Pennsylvania and Maryland to order the IMMray™ PanCan-d test for their patients.
"Many clinicians in Pennsylvania and Maryland have been at the forefront of efforts to enhance surveillance for pancreatic cancer. We are very happy that these physicians can now utilize IMMray™ PanCan-d to detect pancreatic cancer in at-risk patients at stages 1 and 2. With these permits, we are now able to offer IMMray™ PanCan-d in 48 states," says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc., the US subsidiary of Immunovia AB.
For more information, please contact:
Philipp Mathieu
Acting CEO and President
Email: philipp.mathieu@immunovia.com
Tobias Bülow
Senior Director Investor Relations and Corporate Communications
Email: tobias.bulow@immunovia.com
Tel: +46 736 36 35 74
The information was submitted for publication on May 23, 2022, at 08:30 am CET.
About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:SOURCE Immunovia AB
FAQ
What new permits has Immunovia, Inc. obtained?
How many states is the IMMray™ PanCan-d test available in?
What is the IMMray™ PanCan-d test used for?
Who is the CEO of Immunovia?
What is the significance of the IMMray™ PanCan-d test?
